Addex Reports CHF 6.7M Net Loss for 2025, Cash Balance Drops to CHF 1.6M
ADXN sits 31% above its 52-week low of $5.41.
Summary
Addex Therapeutics reported a significant net loss of CHF 6.7 million for the full year 2025, a sharp reversal from a net profit of CHF 7.1 million in 2024. The net loss from continuing operations also widened to CHF 6.8 million. Critically, the company's cash and cash equivalents plummeted to CHF 1.6 million as of December 31, 2025, down from CHF 3.3 million the previous year. This extremely low cash position for a clinical-stage biopharmaceutical company with a sub-$10 million market cap indicates a precarious financial runway and an imminent need for significant dilutive financing. While the corporate update highlighted progress in its GABAB PAM chronic cough candidate, regained rights to a Phase 2 mGlu2 PAM asset, and new partnerships, these positive pipeline developments are largely overshadowed by the severe financial deterioration and urgent liquidity concerns. Investors will be closely monitoring for any announcements regarding capital raises or strategic financing to address the company's cash burn.
At the time of this announcement, ADXN was trading at $7.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $5.41 to $12.05. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.